Myriad Financial Statements From 2010 to 2026

MYGN Stock

USD 5.12 0.02 0.39%

Myriad Genetics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Myriad Genetics' valuation are provided below:

Gross Profit

580.7 M

Profit Margin

(0.49)

Market Capitalization

475.4 M

Enterprise Value Revenue

0.6797

Revenue

825.3 M

We have found one hundred twenty available fundamental ratios for Myriad Genetics, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Myriad Genetics' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 6th of February 2026, Market Cap is likely to drop to about 835 M. In addition to that, Enterprise Value is likely to drop to about 819.2 M

Myriad Genetics Total Revenue

1.01 Billion

Check Myriad Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Myriad Genetics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.9 M, Total Revenue of 1 B or Gross Profit of 338.4 M, as well as many indicators such as Price To Sales Ratio of 1.62, Dividend Yield of 0.0665 or PTB Ratio of 1.94. Myriad financial statements analysis is a perfect complement when working with Myriad Genetics Valuation or Volatility modules.

Build AI portfolio with Myriad Stock

Check out the analysis of Myriad Genetics Correlation against competitors.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Myriad Genetics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

686.6 M

1.2 B

976.3 M

Slightly volatile

Short and Long Term Debt Total

116.2 M

161.3 M

119.6 M

Slightly volatile

Total Current Liabilities

198.2 M

188.7 M

118.6 M

Slightly volatile

Total Stockholder Equity

537.8 M

806.3 M

736.8 M

Slightly volatile

Property Plant And Equipment Net

208.2 M

198.3 M

92.3 M

Slightly volatile

Accounts Payable

39 M

37.1 M

23.6 M

Slightly volatile

Cash

92.8 M

117.8 M

96.3 M

Slightly volatile

Non Current Assets Total

881 M

839 M

647.2 M

Slightly volatile

Cash And Short Term Investments

206.5 M

117.8 M

209.4 M

Slightly volatile

Common Stock Shares Outstanding

75.8 M

104.2 M

77.7 M

Slightly volatile

Liabilities And Stockholders Equity

686.6 M

1.2 B

976.3 M

Slightly volatile

Non Current Liabilities Total

196.1 M

186.8 M

136 M

Slightly volatile

Other Current Assets

55.4 M

53.9 M

58.2 M

Pretty Stable

Other Stockholder Equity

1.8 B

1.7 B

1 B

Slightly volatile

Total Liabilities

394.2 M

375.5 M

254 M

Slightly volatile

Total Current Assets

307.4 M

342.7 M

358.6 M

Pretty Stable

Short Term Debt

25.1 M

14.7 M

38.8 M

Slightly volatile

Net Receivables

146.3 M

139.4 M

96.9 M

Slightly volatile

Common Stock

667.8 K

1 M

748.9 K

Slightly volatile

Current Deferred Revenue

513 K

540 K

2.8 M

Slightly volatile

Good Will

250.8 M

329.2 M

225.2 M

Slightly volatile

Intangible Assets

336.1 M

301.8 M

290.1 M

Slightly volatile

Long Term Debt

33.9 M

35.6 M

147.5 M

Slightly volatile

Capital Lease Obligations

114.8 M

115.8 M

87 M

Slightly volatile

Net Invested Capital

729.4 M

666.6 M

1 B

Slightly volatile

Property Plant And Equipment Gross

290.6 M

324.3 M

238.7 M

Slightly volatile

Capital Stock

902 K

1 M

772.8 K

Slightly volatile

Non Current Liabilities Other

2.4 M

2.5 M

9.3 M

Pretty Stable

Net Working Capital

143.1 M

120.5 M

182.4 M

Slightly volatile

Myriad Genetics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

73.9 M

70.4 M

42.5 M

Slightly volatile

Total Revenue

1 B

963.2 M

685.9 M

Slightly volatile

Gross Profit

338.4 M

673.2 M

498.7 M

Slightly volatile

Other Operating Expenses

1.2 B

1.1 B

687.6 M

Slightly volatile

Research Development

136.9 M

130.4 M

76.4 M

Slightly volatile

Total Operating Expenses

856 M

815.2 M

522.2 M

Slightly volatile

Selling General Administrative

390.7 M

317.3 M

385.2 M

Pretty Stable

Net Income Applicable To Common Shares

159.7 M

202.7 M

163.8 M

Slightly volatile

Non Operating Income Net Other

3.5 M

3.1 M

3.8 M

Slightly volatile

Interest Income

1.7 M

1.5 M

2.4 M

Slightly volatile

Reconciled Depreciation

49.7 M

55.1 M

66.2 M

Slightly volatile

Selling And Marketing Expenses

308 M

326.7 M

275.1 M

Slightly volatile

Myriad Genetics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

89.8 M

162 M

100.3 M

Slightly volatile

Depreciation

73.9 M

70.4 M

42.6 M

Slightly volatile

Capital Expenditures

35.9 M

34.2 M

20.3 M

Slightly volatile

End Period Cash Flow

92.1 M

128.7 M

97.2 M

Slightly volatile

Dividends Paid

288.8 M

306 M

364.6 M

Slightly volatile

Change Receivables

51.7 M

58.1 M

63.5 M

Slightly volatile

Exchange Rate Changes

400 K

450 K

491.2 K

Slightly volatile

Cash And Cash Equivalents Changes

56.4 M

63.5 M

69.3 M

Slightly volatile

Cash Flows Other Operating

47.8 M

53.7 M

58.6 M

Slightly volatile

Change To Operating Activities

3.5 M

4 M

4.3 M

Slightly volatile

Change To Netincome

57.1 M

64.3 M

70.1 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.62

1.71

4.087

Slightly volatile

Dividend Yield

0.0665

0.11

0.1097

Very volatile

PTB Ratio

1.94

2.04

2.3551

Slightly volatile

Days Sales Outstanding

43.78

47.53

50.1975

Slightly volatile

Book Value Per Share

5.48

6.96

9.8789

Pretty Stable

Average Payables

5.6 M

9.4 M

9.7 M

Very volatile

Stock Based Compensation To Revenue

0.0553

0.0684

0.0485

Slightly volatile

Capex To Depreciation

1.01

0.56

0.6806

Slightly volatile

PB Ratio

1.94

2.04

2.3551

Slightly volatile

EV To Sales

1.67

1.76

3.9772

Slightly volatile

Sales General And Administrative To Revenue

0.61

0.38

0.6058

Slightly volatile

Research And Ddevelopement To Revenue

0.15

0.16

0.223

Slightly volatile

Capex To Revenue

0.0387

0.0408

0.0847

Slightly volatile

Cash Per Share

1.86

1.02

2.2275

Slightly volatile

Payout Ratio

1.67

1.27

1.1983

Very volatile

Current Ratio

1.98

2.09

3.8951

Slightly volatile

Receivables Turnover

9.6

7.95

8.5536

Slightly volatile

Shareholders Equity Per Share

5.48

6.96

9.8793

Pretty Stable

Debt To Equity

0.1

0.18

0.1456

Slightly volatile

Capex Per Share

0.31

0.3

0.2545

Slightly volatile

Average Receivables

14.1 M

13.4 M

14 M

Slightly volatile

Revenue Per Share

4.21

8.32

8.4163

Pretty Stable

Interest Debt Per Share

1.07

1.42

1.2536

Slightly volatile

Debt To Assets

0.0712

0.12

0.0975

Slightly volatile

Graham Number

3.91

4.11

10.2074

Slightly volatile

Operating Cycle

87.52

83.35

101

Very volatile

Price Book Value Ratio

1.94

2.04

2.3551

Slightly volatile

Dividend Payout Ratio

1.67

1.27

1.1983

Very volatile

Ebt Per Ebit

0.72

0.92

0.9396

Very volatile

Company Equity Multiplier

0.98

1.32

1.2954

Slightly volatile

Long Term Debt To Capitalization

0.0722

0.0481

0.0986

Very volatile

Total Debt To Capitalization

0.088

0.15

0.1232

Slightly volatile

Debt Equity Ratio

0.1

0.18

0.1456

Slightly volatile

Quick Ratio

1.8

1.9

3.6789

Slightly volatile

Net Income Per E B T

0.89

1.19

0.817

Slightly volatile

Cash Ratio

0.68

0.72

0.9515

Slightly volatile

Days Of Sales Outstanding

43.78

47.53

50.1975

Slightly volatile

Price To Book Ratio

1.94

2.04

2.3551

Slightly volatile

Fixed Asset Turnover

7.19

4.37

10.813

Slightly volatile

Debt Ratio

0.0712

0.12

0.0975

Slightly volatile

Price Sales Ratio

1.62

1.71

4.087

Slightly volatile

Asset Turnover

0.43

0.73

0.6273

Very volatile

Gross Profit Margin

0.92

0.8

0.8031

Slightly volatile

Price Fair Value

1.94

2.04

2.3551

Slightly volatile

Myriad Genetics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

835 M

1.1 B

1.3 B

Pretty Stable

Enterprise Value

819.2 M

1.1 B

1.4 B

Pretty Stable

Myriad Fundamental Market Drivers

	Forward Price Earnings	54.0541
	Cash And Short Term Investments	102.4 M

Myriad Upcoming Events

	27th of February 2024 Upcoming Quarterly Report	View
	1st of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	27th of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Myriad Genetics Financial Statements

Myriad Genetics investors utilize fundamental indicators, such as revenue or net income, to predict how Myriad Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	540 K	513 K
Total Revenue	963.2 M	1 B
Cost Of Revenue	290 M	304.5 M
Stock Based Compensation To Revenue	0.07	0.06
Sales General And Administrative To Revenue	0.38	0.61
Research And Ddevelopement To Revenue	0.16	0.15
Capex To Revenue	0.04	0.04
Revenue Per Share	8.32	4.21
Ebit Per Revenue	(0.13)	(0.14)

Pair Trading with Myriad Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Myriad Stock

0.81	DWTX	Dogwood Therapeutics	Pair Corr
0.68	EDIT	Editas Medicine	Pair Corr

Moving against Myriad Stock

0.6	IMMP	Immutep Ltd ADR	Pair Corr
0.54	ENGN	enGene Holdings Common	Pair Corr
0.34	DSGN	Design Therapeutics	Pair Corr
0.34	63E	ONWARD MEDICAL BV	Pair Corr

The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.

The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:

How To Invest In Myriad

Details

Is Myriad Stock a good investment?

Details

What is Myriad Genetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Myriad Genetics Correlation against competitors.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Will Biotechnology sector continue expanding? Could Myriad diversify its offerings? Factors like these will boost the valuation of Myriad Genetics. Expected growth trajectory for Myriad significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Myriad Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(4.35)

Revenue Per Share

8.976

Quarterly Revenue Growth

(0.04)

Return On Assets

(0.06)

Return On Equity

(0.73)

Investors evaluate Myriad Genetics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Myriad Genetics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Myriad Genetics' market price to deviate significantly from intrinsic value.

Understanding that Myriad Genetics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Myriad Genetics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Myriad Genetics' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Myriad Financial Statements From 2010 to 2026

Myriad Genetics Total Revenue

1.01 Billion

Myriad Genetics Balance Sheet

Myriad Genetics Income Statement

Myriad Genetics Cash Flow Statement

Financial Ratios

Myriad Genetics Valuation Data

Myriad Fundamental Market Drivers

Myriad Upcoming Events

About Myriad Genetics Financial Statements

Pair Trading with Myriad Genetics

Moving together with Myriad Stock

Moving against Myriad Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY